CMB International raised the target price for Hansoh Pharma (03692) to HKD25.24 from HKD24.11 and maintained the "buy" rating.
The research house said it believes that Hansoh has successfully developed a robust pipeline of GLP-1 assets. The collaboration with MSD will accelerate the development of HS-10535 and unlock global potential.
23/12/2024 15:55
{I-bank focus}CMB raises Hansoh Pharma (03692) to HKD25.24
Previous︰24/12/2024 14:34 {I-bank focus}Morgan lowers Baiyunshan Ph (00874) to HKD21.4
Next︰23/12/2024 15:14 {I-bank focus}CCB lowers Shenzhou Intl (02313) to HKD83
24/12/2024 15:21 {I-bank focus}Morgan lowers Sh Pharma (02607) to HKD17
20/12/2024 15:52 {I-bank focus}BOCI raises WB (09898) to HKD79
20/12/2024 15:16 {I-bank focus}UBS lowers Zoomlion (01157) to HKD6.1
20/12/2024 14:41 {I-bank focus}Daiwa upgrades CKI Holdings (01038) to "buy"
19/12/2024 15:58 {I-bank focus}Citi raises Guangdong Inv (00270) to HKD7.3
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
